Floatz logo

5-azacytidine

Sarcomas

National Cancer Institute (NCI)Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

109 Active assets in the Sarcomas cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB
Cyclophosphamide
Essen Biotech
Phase 2BB
Ifosfamide
City of Hope Medical Center
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Roswell Park Cancer Institute
Phase 2BB
Carboplatin
OHSU Knight Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

5-azacytidine is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BB
Indicative ·
70 / 100
View asset →
Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaDormant
BB
Indicative ·
65 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →